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The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have
recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal
antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) and believe this therapy will have broad
application in humans.
There is currently a great expansion of
interest in treating cancer with immuno-
therapy, in particular manipulating the
anticancer host immune response with
mAbs. The recent FDA approval of the
anti-CTLA-4 mAb (ipilumimab) high-
lights the potential of this type of therapy
and provides opportunities for further
development in this area. An important
function of these immunomodulatory
mAbs is their ability to synergise with
conventional first line therapy to enhance
anti-cancer efficacy.
1 In 2006 our labor-
atory described the combination of an
apoptosis-inducing agonistic anti-TRAIL
receptor mAb with the immunostimula-
tory mAbs anti-CD40 and anti-CD137.
2
Termed trimAb, this therapy led to potent
eradication of subcutaneous solid tumors
in a variety of preclinical mouse models.
Although highly efficacious, induction of
tumor cell apoptosis via an active TRAIL
pathway was found to be essential, thus
limiting the scope of this combination to
TRAIL-sensitive tumors. Considering the
ability of the novel anti-cancer agents,
histone deacetylase inhibitors (HDACi),
to induce potent and specific tumor cell
apoptosis independent of TRAIL sensitiv-
ity,
3,4 we posited that addition of HDACi
may broaden the application of this
combination therapy.
HDACi are an exciting class of anti-
cancer agents demonstrating striking single
agent efficacy against hematological malig-
nancies, butless potent activityagainst solid
tumors. HDACi exert multiple biological
effects including induction of tumor cell
death, blockade of cell cycle progression,
induction of cellular senescence and differ-
entiation.
5 Furthermore, HDACi are able
to enhance tumor cell immunogenicity via
the upregulation of MHC, co-stimulatory
and adhesion molecules, leading to the
generation of IFNc secreting T cells
6 and
enhanced killing of tumor cells by CTLs.
7
This host component of the HDACi-
mediated response is relatively poorly
understood and provides impetus to investi-
gate not only the role of the immune
system in mediating anti-tumor responses
to HDACi, but also to test HDACi in
combination with immunotherapy.
In March 2011,
8 we published a report
demonstrating that the combination of
HDACi with immunostimulatory mAbs is
highly efficacious for the treatment of solid
tumors. The HDACi vorinostat and the
agonistic mAb therapy targeting CD40 and
CD137 (termed here as bimAb), were
individually able to minimally delay the
growth of established solid tumors of
diverse tissue origins including mammary
(4T1.2), colon (MC38) and kidney
(Renca) carcinoma. Strikingly however,
the combination of vorinostat with bimAb
(V/bimAb) induced significant delay in
tumor outgrowth and resulted in regression
of tumors below palpable detection in in up
to56%ofmice.Importantly,V/bimAbwas
also effective against TRAIL-insensitive
tumors. Similar results were achieved with
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the anti-tumor effect of both combinations
was both well tolerated and long lasting,
with mice remaining tumor free for . 100
days. Furthermore, the combination ther-
apy was able to generate a potent and
specific memory response as mice pre-
viously cured with V/bimAb rejected the
same tumor upon rechallenge, however
failed to reject tumors of differing tissue
origins. We therefore found the combina-
tion of HDACi with bimAb to be safe and
highly efficacious against established solid
tumors of diverse tissue origin, regardless of
TRAIL sensitivity.
HDACi have been proposed to possess
immunogenic properties and can dictate
immunogenicity via upregulation of
immune-related molecules on the tumor
cell surface. However, we did not detect
changes in expression of MHC, co-stimu-
latory or regulatory molecules after HDACi
exposure in the tumors we assessed.
Nonetheless, we demonstrated that MC38
tumor cells undergoing apoptosis in
response to vorinostat were phagocytosed
by bone marrow-derived CD11c
+APCs.
Cells overexpressing Bcl-2 were resistant
to vorinostat-induced apoptosis and were
not phagocytosed by APCs. We concluded
HDACi-treated tumor cells were an attract-
ive target for APCs and thus sought to
determine whether HDACi were engaging
the immune system via this mechanism.
Immunogenic cell death is apoptosis-
dependent. Two hallmarks of immuno-
genic cell death are the translocation of
calreticulin from the endoplasmic reticu-
lum to the external plasma membrane and
the release of the nuclear danger signal
HMGB1.
9 We found that calreticulin was
translocated to the surface of vorinostat-
treated MC38 cells and HMGB1 was
released in to the supernatent in an
apoptosis-dependent manner, abrogated
by overexpression of Bcl-2 (unpublished
data). Similar data has been generated
following vorinostat treatment of other
solid tumor cells.
10 Together data suggests
HDACi are indeed multifaceted anti-
cancer agents able to manipulate tumor
cell immunogenicity in multiple ways
including the induction of immunogenic
cell death.
We sought to determine the role of the
immune system in the eradication of
established tumors by V/bimAb given the
potentially immunogenic nature of the
therapy. Therapeutic efficacy of V/bimAb
was abrogated in mice lacking functional
CD8
+ T cells while mice lacking func-
tional NK cells only partially responded.
We also determined an important role for
perforin and IFNc as mice lacking these
effector molecules were completely refract-
ory to therapy. These data highlight the
capacity of HDACi/bimAb to generate
a potent antitumor immune response
mediated by cytotoxic lymphocytes.
These data highlight the capacity of
HDACi/bimAb to generate a potent
antitumour immune response conducted
by cytotoxic lymphocytes. As depicted in
Figure 1, we propose this response is
initiated by tumor cell apoptosis and
potential immunogenic cell death medi-
ated by HDACi, and further enhanced
by bimAb during antigen processing and
presentation and T cell priming.
We believe the results generated by
this study greatly broaden the application
Figure1. Mechanism of action of V/bimAb. We propose V/bimAb potently eradicates solid tumors by acting in three major ways. First, vorinostat
enhances tumor cell (purple cells) sensitivity to NK cells by altering surface expression of immune-related molecules. Second, vorinostat induces tumor
cell-specific apoptosis and immunogenic cell death leading to phagocytosis by APCs. Finally the presence of bimAb enhances antigen processing and
presentation of tumor antigens and heightened priming of CD8
+ T cells. Together, V/bimAb leads eradication of the tumor in a cytotoxic lymphocyte-
dependent manner, utilizing the effector molecules perforin and interferon-c.
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in combination with immunostimulatory
mAb therapy was able to induce regression
of established solid tumors of various
tissue origins in a well-tolerated manner.
Furthermore, eradication of the solid
tumors was found to be immune-
mediated and capable of generating
tumor cell-specific memory, with new
data suggesting both bimAb and HDACi
may initiate this anti-tumor immunity.
Two HDACi, including vorinostat, are
FDA-approved and many others are in
late phase trials. We envisage the data dis-
cussed here will lead to the development
of more rationale-based combination
therapies using these potent pan-HDACi
such as the highly efficacious V/bimAb.
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